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Dear Editor-in-Chief and the Editorial Board,
In their recent article in Advances in Therapy,
Gottschlich et al. [1] concluded that the phy-
tomedicines ELOM-080 and BNO 1016 were
well tolerated and were of comparable effec-
tiveness in treating acute rhinosinusitis (ARS).
We noted the proposed advantages of treatment
with ELOM-080 with great interest, but on
examination of the article we identified several
weaknesses that bring the validity of the
authors’ conclusions into question.
Our primary concern was that the explora-
tory conclusions of a non-interventional study
were being inappropriately presented, in the
manner of a superiority trial, as statistically and
clinically relevant results, whereas non-inter-
ventional studies (NISs) are typically used to
examine the safety of existing treatments rather
than demonstrate the superiority of one treat-
ment over another. Other concerns, which we
discuss in more detail below, include a lack of
clarity of the role of the study sponsor, apparent
bias in the discussion section, inaccuracies in
the figures and incorrect references to previ-
ously published data, and these points lead us
to feel that this article presents a misleading
perspective on the results of the study.
NISs provide a valuable perspective of treat-
ment in real-world practice, but the methodol-
ogy described in the article is beyond the scope
of a conventional NIS. The methods used were
closer to the set-up of a randomised controlled
clinical trial and the results are presented as
such. However, these results have been pre-
sented without the statistical support that
would have been expected of a comparative
trial, such as predetermined endpoints, con-
trolling for the influence of concomitant med-
ications, and whether the correct adjustments
have been made for type 1 error, representative
sampling and multiplicity. Randomised con-
trolled trials comparing treatments rely on
analyses derived from full analysis sets to draw
conclusions on the potential superiority of one
treatment versus another, yet in this study, data
from the full analysis set appear to be missing.
Our other methodological concerns include the
inclusion of Likert scale and numeric rating
scales to record symptoms, the use of which is
typically restricted to clinical trials, and the lack
of a meaningful total symptom score.
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From a study oversight perspective, we were
concerned to read that the corresponding
author of the study is a representative of the
company which manufactures ELOM-080. The
article contains a number of references to
ELOM-080 as a ‘product’ rather than a ‘treat-
ment’, and the discussion of the results shows a
strong bias towards ELOM-080 even though the
results did not show a statistically significant
benefit. These issues suggest a lack of a clear
distinction between the interests of the sponsor
and integrity of the research. Indeed, sections of
the discussion read as if they were advertise-
ments listing the known benefits of one treat-
ment, and these sections seem out of context
with the rest of the discussion.
The figures contain a number of inaccuracies
and omissions. There was an unexplained
inconsistency between the numbers of patients
included in Figs. 1 and 5 (228 patients and 144
patients respectively). Figure 2 gives no mea-
sures of standard errors, does not show the
absolute rating of facial pain, and only provides
data for 7 days, rather than the full 14 days of
the treatment duration. Figure 3 uses inaccurate
calculations of n-fold improvements, which can
result in exaggerated differences between treat-
ments in cases in which the actual differences
between results are marginal. Presenting ‘from-
baseline’ improvements would give a more
accurate representation of the data, and are a
measurement type more typically used in
medical research. As with Fig. 2, Fig. 4 also had
no measures of standard errors or confidence
intervals, and it was not clear how the mean
Likert-scale score could reach 120 when the
individual scores were measured between 0 and
4. Finally, Fig. 5 does include error bars
although it is unclear how these were calculated
given that the measurements are subjective.
We also noted a number of incorrect refer-
ences to previously published data that could
mislead readers. Firstly, the authors incorrectly
suggest that the research carried out by Tesche
et al. was a comparative study between cineole
and BNO 1016, whereas, in fact, Sinupret forte
was the comparator [2]. Secondly, the authors
state that BNO 1016 seems less effective than
BNO 101; however, this assertion is based on
results from independent studies performed
under different conditions and these results are
thus not directly comparable [3–5]. Finally, the
authors’ claim that Sinupret extract inhibits
ciliary beat frequency (CBF) by 10% is mislead-
ing as it ignores data taken from other time
points in the study, namely after 0.5 and 6 h,
when Sinupret extract appeared to stimulate the
CBF [6].
Despite some scepticism, public and profes-
sional confidence in phytomedicines is on the
rise and their use is increasing [7, 8]. It is our
responsibility to present properly reasoned
results to ensure that this confidence is not
misplaced. In light of this letter, we would
strongly encourage the authors to re-examine
the robustness of their arguments.
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